Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects

Diabetes Research and Clinical Practice

Volumn 60, Issue 2, 2003, Pages 131-138

  Ahmad, Jamal ^a   Shafique, Sheelu ^a   Abidi, S M Abbas ^b   Parwez, Iqbal ^b  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Angiotensin converting enzyme inhibitor; Diabetic glomerulopathy; Microalbuminuria; Type 1 diabetes

Indexed keywords

ALBUMIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; EXCRETION; FEMALE; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; HISTOLOGY; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY STRUCTURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORPHOMETRICS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0037404775     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(03)00016-0     Document Type: Article

References (26)

1. Mathiesen E.R., Hommel E., Giese J., Parving H.H. Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetics with microalbuminuria. Br. Med. J. 330:1991;81-87.
2. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 349:1997;1787-1792.
3. Viberti G.C., Hill R.D., Jarrett R.J., Argyropoulos A., Mahmud U., Keen H. Micro-albuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. i:1982;1430-1432.
4. Messent J.W.C., Elliott T.G., Hill R.D., Jarret R.J., Keen H., Viberti G.-C. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int. 41:1992;836-839.
5. Mogensen C.E. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand. J. Clin. Lab. Invest. 36:1976;383-388.
6. Kasiske B.L., Kalil R.S.N., Ma J.Z., Liao M., Keane W.F. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann. Intern. Med. 118:1993;129-138.
7. Zatz R., Dunn B.R., Meyer T.W., Anderson S., Rennke H.G., Brenner B.M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77:1986;1925-1930.
8. Cooper M.E., Allen T.J., Macmillan P.A., Clarke B.E., Jerums G., Doyle A.E. Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia. 32:1989;326-328.
9. World Health Organisation. Diabetes Mellitus: Report of a WHO Study Group, Geneva, World Health Organisation, Tech. Rep. Ser. No. 727, 1985, pp. 1-113.
10. Insua A., Ribstein J., Mimran A. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Postgrad. Med. J. 64:(Suppl 3):1988;59-62.
11. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br. Med. J. 302:1991;210-216.
12. Merck E. Clinical Laboratory: Medico-Chemical Investigation Methods. Eleventh ed: 1974;263-269 Darmstadt, Germany.
13. Mogensen C.E. Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus. Scand. J. Clin. Lab. Invest. 28:1971;91-100.
14. Matoni B.J., Steinman T.I., Mitch W.I. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 27:1985;58-65.
15. Shott S. Statistics for Health Professionals. 1990;57-60 W.H. Saunders, Philadelphia.
16. Macleod J.M., White K.E., Tate H., Bilous R.W. Measurement of glomerular volume in needle biopsy specimens. Nephrol. Dial. Transplant. 15:2000;239-243.
17. Macleod J.M., White K.E., Bilous R.W. Efficient morphometric analysis of glomerular mesangium in insulin-dependent diabetic patients with early nephropathy. Kidney Int. 51:1997;1624-1628. On behalf of the ESPRIT (European Society for the Progression of Renal Disease in Type 1 (Insulin Dependent Diabetes) Study Group.
18. Steffes M.W., Barbosa J., Basgen J.M., Sutherland D.E., Najarian J.S., Mauer S.M. Quantitative glomerular morphology of the normal human kidney. Lab. Invest. 49:1983;82-86.
19. Jensen E.B., Gundersen H.J., Osterby R. Determination of membrane thickness distribution from orthogonal intercepts. J. Microsc. 115:1979;19-33.
20. Steffes M.W., Bilous R.W., Sutherland D.E., Mauer S.M. Cell and matrix components of the mesangium in Type 1 diabetes. Diabetes. 41:1992;679-684.
21. Floretto P., Steffes M.W., Mauer M. Glomerular structure in non-proteinuric IDDM patients with various levels of albuminuria. Diabetes. 43:1994;1358-1364.
22. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. New Engl. J. Med. 329:1993;1456-1462.
23. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 39:1996;587-593.
24. Nankervis A., Nicholls K., Kilmartin G., Allen P., Ratnaike S., Martin F.I.R. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism. 47 (12):(Suppl 1):1988;12-15.
25. Rudberg S., Osterby R., Bangstad H.J., Dahlquist G., Persson B. Effects of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 42:1999;589-595.
26. Baines L.A., Bilous R.W., Tate H., Remuzzi G., Viberti G.C. Effect of 3 years of antihypertensive therapy on renal structure in Type 1 diabetic patients with albuminuria. Diabetes. 50:2001;843-850. On behalf of the ESPRIT (The European Study for the Prevention of Renal Disease in Type 1 Diabetes).